A Phase 2 interventional study of GSK835726 10mg and GSK1004723 1000mcg in Rhinitis, Allergic, Seasonal, sponsored by GlaxoSmithKline. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-02.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Seasonal · GlaxoSmithKline.
Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, this one is the 18th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2009, is one of 7 in phase 2, and was the 24th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 68 across the 26 interventional studies, 46 across the 5 observational. Of the 31 that completed or were terminated, 10 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg oral dose
Drug: GSK835726 10mg
1000mcg nasal spray solution
Drug: GSK1004723 1000mcg
10mg cetirizine as active comparator
Drug: Cetirizine 10mg
placebo
Drug: placebo
GSK835726 10mg tablet
GSK1004723 1000mcg nasal spray solution
Cetirizine 10mg active comparator
placebo to match actives
Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.
Time frame: Day 3 of each treatment period (approximately up to 63 days)
Weighted Mean of the Individual Components of TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed to produce the TNSS at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.
Time frame: Day 3 of each treatment period (approximately up to 63 days)
Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Wet tissue weight assessments was measured as a surrogate marker of nasal secretion at 60, 120, 180, 240, 300 and 360 minutes. The adjusted mean is provided as least square mean.
Time frame: Day 3 of each treatment period (approximately up to 63 days)
Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal congestion was measured on 0-10 centimeter VAS scale (0: no symptoms and 10: the worst possible symptoms) with low score indicates well-being and higher values indicate greater congestion. It was measured at 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes. The adjusted mean is provided as least square mean.
Time frame: Day 3 of each treatment period (approximately up to 63 days)
Mean Forced Expiratory Volume in 1 Second (FEV1)
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. FEV1 was measured at pre-challenge, 60, 120, 180, 240, 300 and 360 minutes.
Time frame: Day 3 of each treatment period (approximately up to 63 days)
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or is associated with liver injury and impaired liver function defined as: alanine aminotransferase \>=3 times upper limit of normal (ULN), and total bilirubin \>=2 times ULN or international normalized ratio more than 1.5.
Time frame: approximately up to 63 days
From June-2009 to August-2009, total of 54 participants were randomized at one site in Germany.
| Milestone | Overall Study |
|---|---|
| Started | 54 |
| Completed | 51 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Investigator discretion | 1 |
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.
| Score on a scale | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3 | 4.9 (4.4 to 5.4) | 4.2 (3.7 to 4.8) | 3.6 (3.1 to 4.1) | 3.5 (3.0 to 4.1) |
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed to produce the TNSS at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.
| Score on a scale | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Nasal Blockage | 1.5 (1.3 to 1.7) | 1.7 (1.5 to 1.8) | 1.3 (1.1 to 1.4) | 1.3 (1.1 to 1.4) |
| Rhinorrhoea | 1.5 (1.3 to 1.7) | 1.3 (1.1 to 1.4) | 1.1 (0.9 to 1.3) | 1.0 (0.9 to 1.2) |
| Nasal Itching | 1.1 (0.9 to 1.3) | 0.9 (0.7 to 1.0) | 0.8 (0.6 to 1.0) | 0.8 (0.6 to 1.0) |
| Sneezing | 0.8 (0.7 to 0.9) | 0.4 (0.3 to 0.6) | 0.5 (0.4 to 0.6) | 0.5 (0.3 to 0.6) |
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Wet tissue weight assessments was measured as a surrogate marker of nasal secretion at 60, 120, 180, 240, 300 and 360 minutes. The adjusted mean is provided as least square mean.
| Grams | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3 | 6.251 (5.198 to 7.304) | 5.210 (4.167 to 6.254) | 4.491 (3.446 to 5.536) | 3.459 (2.406 to 4.512) |
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal congestion was measured on 0-10 centimeter VAS scale (0: no symptoms and 10: the worst possible symptoms) with low score indicates well-being and higher values indicate greater congestion. It was measured at 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes. The adjusted mean is provided as least square mean.
| Score on a scale | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3 | 3.97 (3.36 to 4.57) | 4.29 (3.69 to 4.89) | 2.92 (2.32 to 3.52) | 2.90 (2.29 to 3.51) |
On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. FEV1 was measured at pre-challenge, 60, 120, 180, 240, 300 and 360 minutes.
| Liters | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| FEV1-Pre challenge | 3.908 ± 0.7051 | 3.935 ± 0.6515 | 3.924 ± 0.7055 | 3.932 ± 0.6654 |
| FEV1,1 hour | 3.949 ± 0.7319 | 3.959 ± 0.6804 | 3.948 ± 0.7125 | 3.958 ± 0.6865 |
| FEV1,2 hour | 3.910 ± 0.7161 | 3.948 ± 0.6444 | 3.936 ± 0.7014 | 3.925 ± 0.6829 |
| FEV1,3 hour | 3.901 ± 0.7134 | 3.938 ± 0.6774 | 3.918 ± 0.6941 | 3.899 ± 0.7179 |
| FEV1,4 hour | 3.881 ± 0.7364 | 3.913 ± 0.7083 | 3.903 ± 0.7067 | 3.903 ± 0.7124 |
| FEV1,5 hour | 3.858 ± 0.7314 | 3.890 ± 0.6868 | 3.890 ± 0.6954 | 3.858 ± 0.7406 |
| FEV1,6 hour | 3.914 ± 0.7099 | 3.877 ± 0.6381 | 3.887 ± 0.6894 | 3.868 ± 0.7231 |
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or is associated with liver injury and impaired liver function defined as: alanine aminotransferase \>=3 times upper limit of normal (ULN), and total bilirubin \>=2 times ULN or international normalized ratio more than 1.5.
| Participants | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Any AE | 15 | 53 | 13 | 17 |
| Any SAE | 0 | 0 | 0 | 0 |
Collected over AEs and SAEs were reported throughout the study (approximately up to 63 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/52 (0%) | 0/52 (0%) | 15/52 (28.8%) |
| GSK1004723 1000 µg Once Daily | 0/54 (0%) | 0/54 (0%) | 53/54 (98.1%) |
| GSK835726 10 mg Once Daily | 0/53 (0%) | 0/53 (0%) | 13/53 (24.5%) |
| Cetirizine 10 mg Once Daily | 0/52 (0%) | 0/52 (0%) | 17/52 (32.7%) |
| Event | Placebo | GSK1004723 1000 µg Once Daily | GSK835726 10 mg Once Daily | Cetirizine 10 mg Once Daily |
|---|---|---|---|---|
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 1/52 | 47/54 | 1/53 | 1/52 |
| HeadacheNervous system disorders | 8/52 | 7/54 | 6/53 | 11/52 |
| Lacrimation increasedEye disorders | 0/52 | 5/54 | 0/53 | 0/52 |
| FatigueGeneral disorders | 2/52 | 4/54 | 3/53 | 4/52 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/52 | 4/54 | 0/53 | 1/52 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 2/52 | 4/54 | 0/53 | 0/52 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/52 | 3/54 | 0/53 | 0/52 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/52 | 3/54 | 0/53 | 0/52 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/52 | 1/54 | 0/53 | 2/52 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/52 | 1/54 | 1/53 | 2/52 |
| Age, Continuous(Years) | Overall Study |
|---|---|
| Mean | 37.9 ± 10.92 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 15 |
| Male | 39 |
| Race/Ethnicity, Customized(Participants) | Overall Study |
|---|---|
| White - White/Caucasian/European Heritage | 54 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 8 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK 835726 · GSK 1004723 · Cetirizine
Rhinitis, Allergic, Seasonal →